| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging, Cine | 37 | 2025 | 43 | 9.500 |
Why?
|
| Myocardium | 39 | 2025 | 263 | 9.250 |
Why?
|
| Magnetic Resonance Imaging | 58 | 2025 | 587 | 7.320 |
Why?
|
| Cardiomyopathies | 20 | 2023 | 65 | 5.560 |
Why?
|
| Atrial Fibrillation | 26 | 2026 | 122 | 4.740 |
Why?
|
| Heart Failure | 26 | 2026 | 302 | 4.620 |
Why?
|
| Ventricular Remodeling | 12 | 2025 | 61 | 4.570 |
Why?
|
| Ventricular Dysfunction, Left | 19 | 2026 | 96 | 4.480 |
Why?
|
| Heart Ventricles | 21 | 2025 | 123 | 4.220 |
Why?
|
| Humans | 391 | 2026 | 43102 | 4.110 |
Why?
|
| Cardiomyopathy, Hypertrophic | 13 | 2025 | 25 | 3.840 |
Why?
|
| Middle Aged | 200 | 2026 | 12222 | 3.750 |
Why?
|
| Ventricular Function, Left | 25 | 2025 | 114 | 3.680 |
Why?
|
| Myocardial Infarction | 27 | 2024 | 247 | 3.590 |
Why?
|
| Coronary Artery Disease | 13 | 2026 | 163 | 3.460 |
Why?
|
| Female | 256 | 2026 | 24698 | 3.400 |
Why?
|
| Male | 240 | 2026 | 23409 | 3.360 |
Why?
|
| Taste | 18 | 2020 | 45 | 3.220 |
Why?
|
| Myocarditis | 13 | 2025 | 24 | 3.170 |
Why?
|
| Stroke Volume | 24 | 2026 | 122 | 3.100 |
Why?
|
| Defibrillators, Implantable | 13 | 2024 | 39 | 3.090 |
Why?
|
| Heart Transplantation | 12 | 2025 | 47 | 3.070 |
Why?
|
| Catheter Ablation | 18 | 2025 | 34 | 3.040 |
Why?
|
| Aged | 118 | 2026 | 8214 | 2.970 |
Why?
|
| Mass Spectrometry | 22 | 2017 | 280 | 2.840 |
Why?
|
| Echocardiography | 24 | 2025 | 167 | 2.820 |
Why?
|
| Colonography, Computed Tomographic | 21 | 2011 | 23 | 2.700 |
Why?
|
| Predictive Value of Tests | 36 | 2025 | 440 | 2.690 |
Why?
|
| Cicatrix | 7 | 2025 | 17 | 2.680 |
Why?
|
| Gadolinium DTPA | 15 | 2016 | 18 | 2.620 |
Why?
|
| Tomography, X-Ray Computed | 24 | 2025 | 245 | 2.530 |
Why?
|
| Treatment Outcome | 61 | 2026 | 1604 | 2.340 |
Why?
|
| Adult | 129 | 2026 | 13872 | 2.280 |
Why?
|
| Prospective Studies | 52 | 2025 | 1600 | 2.270 |
Why?
|
| Contrast Media | 26 | 2021 | 103 | 2.250 |
Why?
|
| Coronary Angiography | 13 | 2025 | 96 | 2.190 |
Why?
|
| Aortic Valve Stenosis | 4 | 2025 | 33 | 2.080 |
Why?
|
| Fibrosis | 24 | 2025 | 169 | 2.040 |
Why?
|
| Heart Diseases | 6 | 2023 | 112 | 2.010 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2025 | 22 | 1.990 |
Why?
|
| Fractional Flow Reserve, Myocardial | 3 | 2025 | 21 | 1.960 |
Why?
|
| Technetium Tc 99m Mertiatide | 12 | 2012 | 12 | 1.860 |
Why?
|
| Copper | 6 | 2019 | 134 | 1.660 |
Why?
|
| Retrospective Studies | 55 | 2026 | 2544 | 1.600 |
Why?
|
| Coronary Stenosis | 2 | 2025 | 37 | 1.600 |
Why?
|
| Rheumatic Heart Disease | 2 | 2021 | 4 | 1.380 |
Why?
|
| Leptospirosis | 2 | 2025 | 31 | 1.360 |
Why?
|
| Acute Coronary Syndrome | 4 | 2024 | 42 | 1.360 |
Why?
|
| Cardiomyopathy, Dilated | 5 | 2021 | 30 | 1.330 |
Why?
|
| Image Interpretation, Computer-Assisted | 11 | 2018 | 58 | 1.330 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2022 | 6 | 1.300 |
Why?
|
| Image Enhancement | 11 | 2016 | 37 | 1.300 |
Why?
|
| Electrocardiography | 14 | 2024 | 185 | 1.300 |
Why?
|
| Colonic Polyps | 11 | 2008 | 71 | 1.290 |
Why?
|
| Radioisotope Renography | 8 | 2012 | 9 | 1.290 |
Why?
|
| Time Factors | 30 | 2026 | 1857 | 1.260 |
Why?
|
| Gadolinium | 11 | 2021 | 30 | 1.210 |
Why?
|
| Australia | 18 | 2026 | 103 | 1.200 |
Why?
|
| Colon | 6 | 2019 | 120 | 1.170 |
Why?
|
| Case-Control Studies | 24 | 2023 | 1285 | 1.110 |
Why?
|
| Postoperative Complications | 13 | 2020 | 263 | 1.110 |
Why?
|
| Death, Sudden, Cardiac | 7 | 2024 | 31 | 1.100 |
Why?
|
| Follow-Up Studies | 24 | 2026 | 1067 | 1.100 |
Why?
|
| Radiopharmaceuticals | 13 | 2025 | 62 | 1.090 |
Why?
|
| Kidney | 7 | 2017 | 372 | 1.080 |
Why?
|
| Sensitivity and Specificity | 25 | 2025 | 611 | 1.070 |
Why?
|
| Graft Rejection | 4 | 2025 | 43 | 1.070 |
Why?
|
| Renal Insufficiency | 2 | 2019 | 19 | 1.060 |
Why?
|
| Reproducibility of Results | 29 | 2025 | 1081 | 1.060 |
Why?
|
| Liver | 6 | 2020 | 511 | 1.040 |
Why?
|
| Mitral Valve | 2 | 2025 | 36 | 1.030 |
Why?
|
| Heart Valve Prosthesis | 4 | 2025 | 44 | 1.030 |
Why?
|
| Esophagus | 2 | 2020 | 42 | 0.990 |
Why?
|
| Food Service, Hospital | 1 | 2026 | 2 | 0.970 |
Why?
|
| Probability | 2 | 2024 | 82 | 0.950 |
Why?
|
| Diastole | 5 | 2025 | 47 | 0.950 |
Why?
|
| Quality Control | 5 | 2019 | 42 | 0.940 |
Why?
|
| Heart | 6 | 2019 | 184 | 0.940 |
Why?
|
| Eating | 3 | 2020 | 167 | 0.940 |
Why?
|
| Certification | 2 | 2024 | 21 | 0.930 |
Why?
|
| Atherosclerosis | 2 | 2026 | 169 | 0.930 |
Why?
|
| Stroke | 5 | 2023 | 340 | 0.920 |
Why?
|
| Algorithms | 11 | 2021 | 509 | 0.920 |
Why?
|
| Risk Assessment | 18 | 2026 | 863 | 0.910 |
Why?
|
| Victoria | 17 | 2026 | 17 | 0.910 |
Why?
|
| Aortic Valve | 1 | 2025 | 38 | 0.910 |
Why?
|
| Selenium | 4 | 2013 | 155 | 0.910 |
Why?
|
| Heart-Assist Devices | 5 | 2026 | 37 | 0.910 |
Why?
|
| Adolescent | 34 | 2026 | 6081 | 0.910 |
Why?
|
| Heart Atria | 8 | 2020 | 29 | 0.900 |
Why?
|
| Spectrophotometry, Atomic | 3 | 2016 | 16 | 0.900 |
Why?
|
| Spironolactone | 1 | 2025 | 36 | 0.880 |
Why?
|
| Aged, 80 and over | 21 | 2025 | 2853 | 0.880 |
Why?
|
| Flavoring Agents | 4 | 2010 | 22 | 0.870 |
Why?
|
| Troponin I | 6 | 2020 | 18 | 0.860 |
Why?
|
| Disease Progression | 6 | 2020 | 667 | 0.860 |
Why?
|
| Heart Injuries | 2 | 2014 | 10 | 0.860 |
Why?
|
| Colonic Neoplasms | 5 | 2020 | 223 | 0.840 |
Why?
|
| Databases, Factual | 3 | 2024 | 341 | 0.840 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2025 | 54 | 0.830 |
Why?
|
| Ureteral Obstruction | 4 | 2010 | 16 | 0.830 |
Why?
|
| Young Adult | 25 | 2026 | 5080 | 0.820 |
Why?
|
| Emergency Medical Services | 6 | 2025 | 79 | 0.820 |
Why?
|
| Blood Chemical Analysis | 4 | 2013 | 25 | 0.820 |
Why?
|
| Cardiac Pacing, Artificial | 4 | 2016 | 13 | 0.820 |
Why?
|
| Intestinal Perforation | 3 | 2017 | 11 | 0.810 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 42 | 0.810 |
Why?
|
| Malaria, Falciparum | 2 | 2024 | 90 | 0.800 |
Why?
|
| Muscular Diseases | 1 | 2023 | 22 | 0.800 |
Why?
|
| Diamond | 5 | 2025 | 9 | 0.800 |
Why?
|
| Chest Pain | 11 | 2023 | 49 | 0.780 |
Why?
|
| Iron | 3 | 2019 | 251 | 0.770 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 28 | 0.770 |
Why?
|
| Risk Factors | 26 | 2026 | 3994 | 0.770 |
Why?
|
| Onions | 2 | 2019 | 10 | 0.760 |
Why?
|
| Fusarium | 2 | 2019 | 11 | 0.760 |
Why?
|
| Coronary Circulation | 6 | 2018 | 29 | 0.760 |
Why?
|
| Severity of Illness Index | 15 | 2025 | 719 | 0.750 |
Why?
|
| Acrylamide | 3 | 2008 | 8 | 0.750 |
Why?
|
| Electronic Health Records | 2 | 2021 | 108 | 0.750 |
Why?
|
| Tachycardia, Ventricular | 3 | 2021 | 15 | 0.740 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 310 | 0.740 |
Why?
|
| Rifampin | 1 | 2022 | 8 | 0.740 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2026 | 11 | 0.740 |
Why?
|
| Myocardial Reperfusion | 5 | 2011 | 9 | 0.740 |
Why?
|
| Registries | 8 | 2026 | 437 | 0.740 |
Why?
|
| Rheumatic Fever | 1 | 2021 | 10 | 0.730 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 131 | 0.730 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2017 | 174 | 0.720 |
Why?
|
| Plant Diseases | 2 | 2019 | 65 | 0.720 |
Why?
|
| Pulmonary Valve Insufficiency | 7 | 2025 | 8 | 0.720 |
Why?
|
| Mortality | 1 | 2023 | 175 | 0.710 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2021 | 31 | 0.710 |
Why?
|
| Liver Neoplasms | 4 | 2018 | 224 | 0.710 |
Why?
|
| Thoracic Injuries | 2 | 2022 | 11 | 0.710 |
Why?
|
| Ventricular Function, Right | 7 | 2025 | 33 | 0.710 |
Why?
|
| Data Collection | 2 | 2020 | 210 | 0.700 |
Why?
|
| Child | 23 | 2026 | 3443 | 0.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2019 | 760 | 0.690 |
Why?
|
| Boron | 4 | 2025 | 10 | 0.690 |
Why?
|
| Commerce | 3 | 2012 | 95 | 0.690 |
Why?
|
| Ethanol | 3 | 2009 | 224 | 0.690 |
Why?
|
| Echocardiography, Doppler | 4 | 2014 | 41 | 0.690 |
Why?
|
| Incidence | 9 | 2026 | 1078 | 0.690 |
Why?
|
| Tuberculosis | 1 | 2022 | 78 | 0.680 |
Why?
|
| Emergency Service, Hospital | 9 | 2023 | 278 | 0.680 |
Why?
|
| Bile Ducts | 2 | 2014 | 4 | 0.680 |
Why?
|
| Triage | 1 | 2021 | 34 | 0.670 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 94 | 0.670 |
Why?
|
| Natural Language Processing | 1 | 2021 | 21 | 0.670 |
Why?
|
| Beriberi | 1 | 2020 | 1 | 0.670 |
Why?
|
| Transketolase | 1 | 2020 | 2 | 0.670 |
Why?
|
| Astronauts | 1 | 2020 | 6 | 0.670 |
Why?
|
| Dietary Fats | 4 | 2011 | 117 | 0.660 |
Why?
|
| Models, Economic | 1 | 2020 | 28 | 0.650 |
Why?
|
| Atrial Appendage | 1 | 2020 | 4 | 0.650 |
Why?
|
| Hepatitis E | 1 | 2020 | 3 | 0.650 |
Why?
|
| Hepatitis E virus | 1 | 2020 | 3 | 0.650 |
Why?
|
| Health Services Research | 2 | 2020 | 161 | 0.650 |
Why?
|
| Cohort Studies | 20 | 2023 | 1759 | 0.640 |
Why?
|
| Endemic Diseases | 1 | 2020 | 23 | 0.640 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2020 | 465 | 0.640 |
Why?
|
| Clozapine | 7 | 2012 | 17 | 0.630 |
Why?
|
| Remote Consultation | 1 | 2019 | 8 | 0.630 |
Why?
|
| Barrett Esophagus | 1 | 2020 | 29 | 0.620 |
Why?
|
| Antilymphocyte Serum | 1 | 2019 | 4 | 0.620 |
Why?
|
| Erythrocytes | 1 | 2020 | 126 | 0.620 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2022 | 30 | 0.620 |
Why?
|
| Glucosides | 1 | 2019 | 21 | 0.610 |
Why?
|
| Ambulances | 4 | 2023 | 7 | 0.610 |
Why?
|
| Crohn Disease | 3 | 2017 | 71 | 0.600 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2016 | 21 | 0.600 |
Why?
|
| Recovery of Function | 6 | 2025 | 107 | 0.590 |
Why?
|
| Prosthesis Design | 6 | 2025 | 47 | 0.590 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 50 | 0.590 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 163 | 0.580 |
Why?
|
| Electric Countershock | 3 | 2018 | 12 | 0.580 |
Why?
|
| Artifacts | 4 | 2014 | 23 | 0.570 |
Why?
|
| Heart Defects, Congenital | 5 | 2022 | 72 | 0.560 |
Why?
|
| Hemorrhage | 2 | 2017 | 55 | 0.560 |
Why?
|
| Shock, Cardiogenic | 2 | 2016 | 10 | 0.560 |
Why?
|
| Ultrasonography | 6 | 2017 | 135 | 0.560 |
Why?
|
| Maillard Reaction | 4 | 2018 | 7 | 0.550 |
Why?
|
| Neuroma, Acoustic | 1 | 2017 | 2 | 0.550 |
Why?
|
| Sucrose | 3 | 2007 | 33 | 0.550 |
Why?
|
| Diagnosis, Differential | 10 | 2014 | 238 | 0.550 |
Why?
|
| Acute Disease | 6 | 2021 | 155 | 0.550 |
Why?
|
| Immunoglobulin G | 4 | 2025 | 259 | 0.550 |
Why?
|
| Hearing | 1 | 2017 | 11 | 0.550 |
Why?
|
| Kidney Diseases | 6 | 2012 | 172 | 0.540 |
Why?
|
| Pattern Recognition, Automated | 5 | 2010 | 32 | 0.540 |
Why?
|
| Creatinine | 4 | 2019 | 102 | 0.540 |
Why?
|
| Troponin | 7 | 2024 | 17 | 0.530 |
Why?
|
| Antipsychotic Agents | 7 | 2012 | 80 | 0.530 |
Why?
|
| Diagnostic Imaging | 5 | 2018 | 53 | 0.530 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 2 | 0.530 |
Why?
|
| Body Surface Potential Mapping | 3 | 2017 | 4 | 0.530 |
Why?
|
| Smell | 5 | 2020 | 40 | 0.530 |
Why?
|
| Incidental Findings | 6 | 2011 | 12 | 0.520 |
Why?
|
| Hot Temperature | 5 | 2022 | 141 | 0.520 |
Why?
|
| Population Dynamics | 3 | 2024 | 50 | 0.520 |
Why?
|
| Colonic Diseases | 2 | 2008 | 11 | 0.520 |
Why?
|
| Pneumoperitoneum | 1 | 2017 | 1 | 0.520 |
Why?
|
| Zinc | 3 | 2008 | 131 | 0.520 |
Why?
|
| Glutathione | 3 | 2014 | 171 | 0.520 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 195 | 0.510 |
Why?
|
| Temperature | 6 | 2022 | 313 | 0.510 |
Why?
|
| Occupational Exposure | 5 | 2017 | 91 | 0.510 |
Why?
|
| Aging | 3 | 2020 | 783 | 0.510 |
Why?
|
| Volatilization | 10 | 2009 | 23 | 0.510 |
Why?
|
| Infant | 14 | 2025 | 1175 | 0.510 |
Why?
|
| Mass Screening | 4 | 2020 | 541 | 0.500 |
Why?
|
| Hip Prosthesis | 3 | 2016 | 8 | 0.500 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 6 | 2019 | 9 | 0.500 |
Why?
|
| Arsenicals | 2 | 2014 | 87 | 0.500 |
Why?
|
| Animals | 34 | 2025 | 16992 | 0.490 |
Why?
|
| Water | 7 | 2022 | 316 | 0.490 |
Why?
|
| ROC Curve | 7 | 2025 | 159 | 0.480 |
Why?
|
| Prognosis | 9 | 2024 | 861 | 0.480 |
Why?
|
| Titanium | 1 | 2016 | 48 | 0.480 |
Why?
|
| Furosemide | 2 | 2007 | 12 | 0.480 |
Why?
|
| Exercise | 6 | 2012 | 692 | 0.480 |
Why?
|
| Scrub Typhus | 1 | 2015 | 6 | 0.470 |
Why?
|
| Orientia tsutsugamushi | 1 | 2015 | 7 | 0.470 |
Why?
|
| New Zealand | 7 | 2026 | 32 | 0.470 |
Why?
|
| Diuretics | 2 | 2007 | 51 | 0.470 |
Why?
|
| Meningitis | 1 | 2015 | 10 | 0.470 |
Why?
|
| Jaundice | 1 | 2015 | 7 | 0.460 |
Why?
|
| Patient Selection | 3 | 2016 | 205 | 0.460 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 44 | 0.460 |
Why?
|
| Giant Cell Arteritis | 2 | 2025 | 4 | 0.460 |
Why?
|
| Child, Preschool | 8 | 2025 | 1546 | 0.450 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 67 | 0.450 |
Why?
|
| Food Analysis | 2 | 2005 | 34 | 0.450 |
Why?
|
| Exercise Test | 5 | 2013 | 74 | 0.450 |
Why?
|
| Cost-Benefit Analysis | 7 | 2023 | 179 | 0.450 |
Why?
|
| Quality of Life | 6 | 2026 | 616 | 0.450 |
Why?
|
| Models, Cardiovascular | 5 | 2025 | 98 | 0.450 |
Why?
|
| Sarcoidosis | 1 | 2015 | 11 | 0.450 |
Why?
|
| Nephritis, Interstitial | 1 | 2015 | 7 | 0.450 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2014 | 10 | 0.450 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2014 | 2 | 0.450 |
Why?
|
| Contusions | 1 | 2014 | 3 | 0.440 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2012 | 94 | 0.440 |
Why?
|
| Acoustics | 3 | 2011 | 17 | 0.440 |
Why?
|
| Coronary Artery Bypass | 2 | 2025 | 47 | 0.440 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 2 | 2019 | 2 | 0.440 |
Why?
|
| Pulmonary Valve | 4 | 2025 | 4 | 0.440 |
Why?
|
| Models, Chemical | 3 | 2018 | 204 | 0.430 |
Why?
|
| Bile Duct Diseases | 1 | 2014 | 2 | 0.430 |
Why?
|
| Perception | 3 | 2005 | 215 | 0.430 |
Why?
|
| Electrodiagnosis | 1 | 2014 | 1 | 0.430 |
Why?
|
| Liver Transplantation | 3 | 2020 | 37 | 0.420 |
Why?
|
| Microvessels | 2 | 2017 | 31 | 0.420 |
Why?
|
| Spices | 1 | 2014 | 9 | 0.420 |
Why?
|
| Silver | 2 | 2012 | 61 | 0.420 |
Why?
|
| Psychotic Disorders | 2 | 2012 | 71 | 0.420 |
Why?
|
| Cisplatin | 1 | 2014 | 98 | 0.420 |
Why?
|
| Mouth | 4 | 2011 | 54 | 0.420 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2017 | 58 | 0.420 |
Why?
|
| Methamphetamine | 1 | 2016 | 166 | 0.410 |
Why?
|
| Methylcellulose | 3 | 2006 | 7 | 0.410 |
Why?
|
| Receptors, Odorant | 2 | 2011 | 44 | 0.410 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2013 | 1 | 0.410 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2013 | 3 | 0.410 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 17 | 0.410 |
Why?
|
| Biopsy | 4 | 2025 | 177 | 0.410 |
Why?
|
| Milk | 3 | 2018 | 56 | 0.400 |
Why?
|
| Tetralogy of Fallot | 3 | 2025 | 5 | 0.400 |
Why?
|
| Societies, Medical | 6 | 2024 | 74 | 0.400 |
Why?
|
| Supine Position | 2 | 2017 | 6 | 0.400 |
Why?
|
| Expert Systems | 3 | 2008 | 11 | 0.400 |
Why?
|
| Ceruloplasmin | 3 | 2012 | 15 | 0.400 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2013 | 21 | 0.400 |
Why?
|
| Lead | 2 | 2006 | 100 | 0.400 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2013 | 21 | 0.400 |
Why?
|
| Nutritional Status | 3 | 2014 | 119 | 0.400 |
Why?
|
| Kidney Function Tests | 2 | 2010 | 32 | 0.390 |
Why?
|
| Colorectal Neoplasms | 6 | 2011 | 512 | 0.390 |
Why?
|
| Peptide Fragments | 3 | 2014 | 307 | 0.390 |
Why?
|
| Communications Media | 1 | 2012 | 1 | 0.390 |
Why?
|
| Solutions | 3 | 2008 | 65 | 0.390 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 43 | 0.390 |
Why?
|
| Health Personnel | 1 | 2016 | 277 | 0.390 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 49 | 0.390 |
Why?
|
| International Classification of Diseases | 2 | 2025 | 27 | 0.390 |
Why?
|
| Organizations | 1 | 2012 | 8 | 0.390 |
Why?
|
| Drug Monitoring | 4 | 2015 | 69 | 0.390 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2012 | 4 | 0.390 |
Why?
|
| Systole | 5 | 2018 | 67 | 0.380 |
Why?
|
| Gels | 2 | 2015 | 45 | 0.380 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2016 | 26 | 0.380 |
Why?
|
| Lipids | 2 | 2014 | 256 | 0.380 |
Why?
|
| Stomach | 1 | 2012 | 50 | 0.380 |
Why?
|
| Communication Barriers | 1 | 2012 | 60 | 0.370 |
Why?
|
| Argyria | 1 | 2012 | 2 | 0.370 |
Why?
|
| Age Factors | 9 | 2026 | 1154 | 0.370 |
Why?
|
| Wine | 2 | 2009 | 9 | 0.370 |
Why?
|
| Procollagen | 2 | 2014 | 4 | 0.370 |
Why?
|
| Stents | 3 | 2025 | 67 | 0.360 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2016 | 17 | 0.360 |
Why?
|
| Ventricular Function | 2 | 2014 | 8 | 0.350 |
Why?
|
| Radiographic Image Enhancement | 2 | 2014 | 7 | 0.350 |
Why?
|
| Solanum tuberosum | 3 | 2005 | 22 | 0.340 |
Why?
|
| Pulmonary Veins | 3 | 2016 | 6 | 0.340 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2012 | 54 | 0.340 |
Why?
|
| Pancreatic Cyst | 1 | 2011 | 7 | 0.340 |
Why?
|
| Double-Blind Method | 5 | 2025 | 317 | 0.340 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2010 | 11 | 0.340 |
Why?
|
| Lymphoma, B-Cell | 2 | 2010 | 28 | 0.340 |
Why?
|
| Deglutition Disorders | 2 | 2012 | 25 | 0.340 |
Why?
|
| Radiography, Abdominal | 1 | 2010 | 7 | 0.340 |
Why?
|
| Fatty Liver | 2 | 2010 | 77 | 0.330 |
Why?
|
| Early Diagnosis | 4 | 2021 | 68 | 0.330 |
Why?
|
| Cardiac Volume | 1 | 2010 | 4 | 0.330 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 8 | 0.320 |
Why?
|
| Multiple Myeloma | 2 | 2023 | 48 | 0.320 |
Why?
|
| Adenoma | 3 | 2008 | 96 | 0.320 |
Why?
|
| Hepatic Veins | 2 | 2020 | 2 | 0.320 |
Why?
|
| Carbon Dioxide | 2 | 2007 | 86 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 432 | 0.320 |
Why?
|
| Jugular Veins | 2 | 2020 | 7 | 0.320 |
Why?
|
| Osteoporosis, Postmenopausal | 3 | 2015 | 21 | 0.320 |
Why?
|
| Calibration | 3 | 2023 | 63 | 0.320 |
Why?
|
| DNA | 2 | 2025 | 592 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 4 | 2025 | 223 | 0.310 |
Why?
|
| Tachycardia | 4 | 2021 | 11 | 0.310 |
Why?
|
| Colloids | 3 | 2012 | 15 | 0.310 |
Why?
|
| Cardiology | 3 | 2024 | 18 | 0.310 |
Why?
|
| Cross-Sectional Studies | 10 | 2025 | 3156 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 863 | 0.310 |
Why?
|
| Colonoscopy | 7 | 2008 | 122 | 0.310 |
Why?
|
| Veterinary Medicine | 1 | 2009 | 3 | 0.310 |
Why?
|
| Osteoarthritis | 1 | 2009 | 25 | 0.300 |
Why?
|
| Magnetics | 1 | 2009 | 43 | 0.300 |
Why?
|
| Alcohol Drinking | 3 | 2020 | 609 | 0.300 |
Why?
|
| No-Reflow Phenomenon | 2 | 2024 | 2 | 0.300 |
Why?
|
| Pancreas | 3 | 2016 | 45 | 0.300 |
Why?
|
| Ventricular Outflow Obstruction | 3 | 2016 | 8 | 0.300 |
Why?
|
| Multiple Trauma | 2 | 2022 | 8 | 0.300 |
Why?
|
| Edema | 1 | 2009 | 26 | 0.300 |
Why?
|
| Analysis of Variance | 5 | 2013 | 575 | 0.300 |
Why?
|
| Air | 3 | 2016 | 19 | 0.300 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1019 | 0.300 |
Why?
|
| Dopamine | 2 | 2021 | 275 | 0.290 |
Why?
|
| Complementary Therapies | 1 | 2009 | 51 | 0.290 |
Why?
|
| Brucella | 3 | 2018 | 5 | 0.290 |
Why?
|
| Survival Analysis | 3 | 2019 | 368 | 0.290 |
Why?
|
| Pilot Projects | 6 | 2019 | 760 | 0.290 |
Why?
|
| Guideline Adherence | 2 | 2025 | 98 | 0.290 |
Why?
|
| Cattle | 3 | 2019 | 498 | 0.290 |
Why?
|
| Models, Statistical | 3 | 2023 | 195 | 0.290 |
Why?
|
| Personal Satisfaction | 1 | 2009 | 76 | 0.290 |
Why?
|
| Fluorosis, Dental | 3 | 2012 | 5 | 0.290 |
Why?
|
| Phase Transition | 1 | 2008 | 8 | 0.290 |
Why?
|
| Heart Conduction System | 3 | 2019 | 15 | 0.290 |
Why?
|
| Hospitals | 2 | 2023 | 117 | 0.280 |
Why?
|
| Fruit | 3 | 2007 | 178 | 0.280 |
Why?
|
| Consensus | 7 | 2022 | 48 | 0.280 |
Why?
|
| Aspirin | 3 | 2025 | 89 | 0.280 |
Why?
|
| Pacemaker, Artificial | 2 | 2022 | 18 | 0.280 |
Why?
|
| Food Handling | 2 | 2005 | 35 | 0.280 |
Why?
|
| Animal Communication | 1 | 2008 | 7 | 0.280 |
Why?
|
| Ribose | 2 | 2018 | 11 | 0.280 |
Why?
|
| Chi-Square Distribution | 6 | 2016 | 236 | 0.280 |
Why?
|
| Heart Failure, Systolic | 2 | 2023 | 4 | 0.280 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2008 | 2 | 0.280 |
Why?
|
| Reference Values | 7 | 2017 | 211 | 0.280 |
Why?
|
| Software | 6 | 2014 | 236 | 0.280 |
Why?
|
| Infant, Newborn | 8 | 2025 | 972 | 0.270 |
Why?
|
| Parent-Child Relations | 1 | 2009 | 127 | 0.270 |
Why?
|
| Food | 2 | 2006 | 103 | 0.270 |
Why?
|
| Coronary Disease | 2 | 2006 | 123 | 0.270 |
Why?
|
| Prone Position | 1 | 2007 | 5 | 0.270 |
Why?
|
| Primary Prevention | 2 | 2019 | 63 | 0.270 |
Why?
|
| Automation | 3 | 2017 | 22 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 2 | 2014 | 218 | 0.270 |
Why?
|
| Ureteral Calculi | 2 | 2017 | 3 | 0.270 |
Why?
|
| Intra-Abdominal Fat | 1 | 2008 | 46 | 0.270 |
Why?
|
| Gelatin | 1 | 2007 | 17 | 0.270 |
Why?
|
| Cardiovascular Diseases | 4 | 2018 | 749 | 0.270 |
Why?
|
| Oxidative Stress | 5 | 2024 | 1003 | 0.260 |
Why?
|
| Electrodes | 3 | 2025 | 59 | 0.260 |
Why?
|
| Physicians | 2 | 2022 | 188 | 0.260 |
Why?
|
| Ureter | 2 | 2017 | 6 | 0.260 |
Why?
|
| Vascular Resistance | 3 | 2015 | 36 | 0.260 |
Why?
|
| Meat | 2 | 2004 | 46 | 0.260 |
Why?
|
| Body Mass Index | 6 | 2018 | 925 | 0.260 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 59 | 0.260 |
Why?
|
| Outpatients | 2 | 2022 | 37 | 0.260 |
Why?
|
| Brucellosis | 2 | 2017 | 8 | 0.260 |
Why?
|
| Tongue | 1 | 2007 | 16 | 0.260 |
Why?
|
| Patient Discharge | 2 | 2025 | 128 | 0.260 |
Why?
|
| Myocardial Revascularization | 2 | 2025 | 7 | 0.250 |
Why?
|
| Hysterectomy | 2 | 2017 | 38 | 0.250 |
Why?
|
| C-Reactive Protein | 4 | 2011 | 167 | 0.250 |
Why?
|
| Kinetics | 7 | 2017 | 695 | 0.250 |
Why?
|
| Tea | 1 | 2007 | 46 | 0.250 |
Why?
|
| Emulsions | 4 | 2016 | 36 | 0.250 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 252 | 0.250 |
Why?
|
| Threshold Limit Values | 1 | 2006 | 2 | 0.250 |
Why?
|
| Thyroid Hormones | 2 | 2017 | 35 | 0.250 |
Why?
|
| Organotechnetium Compounds | 1 | 2006 | 9 | 0.250 |
Why?
|
| Bone Density Conservation Agents | 3 | 2015 | 28 | 0.250 |
Why?
|
| Arteriovenous Malformations | 1 | 2006 | 2 | 0.250 |
Why?
|
| Nevus, Blue | 1 | 2006 | 2 | 0.250 |
Why?
|
| Exercise Therapy | 1 | 2007 | 87 | 0.240 |
Why?
|
| Occupational Health | 1 | 2006 | 32 | 0.240 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 90 | 0.240 |
Why?
|
| Amino Acids | 5 | 2024 | 148 | 0.240 |
Why?
|
| Sodium Chloride | 3 | 2017 | 54 | 0.240 |
Why?
|
| Esophageal Achalasia | 1 | 2025 | 3 | 0.240 |
Why?
|
| Hospitals, Pediatric | 1 | 2026 | 22 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2013 | 1124 | 0.240 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2026 | 14 | 0.240 |
Why?
|
| Acids | 1 | 2006 | 19 | 0.240 |
Why?
|
| Coronary Restenosis | 1 | 2025 | 28 | 0.240 |
Why?
|
| Genotype | 3 | 2019 | 800 | 0.240 |
Why?
|
| Carbon | 2 | 2025 | 128 | 0.240 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 420 | 0.240 |
Why?
|
| Body Surface Area | 1 | 2025 | 4 | 0.240 |
Why?
|
| Qualitative Research | 2 | 2026 | 574 | 0.240 |
Why?
|
| Microcirculation | 5 | 2011 | 40 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2025 | 77 | 0.230 |
Why?
|
| Withholding Treatment | 1 | 2026 | 30 | 0.230 |
Why?
|
| Sensory Thresholds | 1 | 2005 | 13 | 0.230 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 24 | 0.230 |
Why?
|
| Oxygen | 3 | 2016 | 218 | 0.230 |
Why?
|
| Travel | 1 | 2025 | 36 | 0.230 |
Why?
|
| Heart Arrest | 1 | 2026 | 52 | 0.230 |
Why?
|
| Streptococcus pyogenes | 1 | 2025 | 29 | 0.230 |
Why?
|
| Bread | 1 | 2005 | 4 | 0.230 |
Why?
|
| Pulmonary Artery | 3 | 2017 | 32 | 0.230 |
Why?
|
| Reoperation | 2 | 2020 | 34 | 0.230 |
Why?
|
| Referral and Consultation | 2 | 2025 | 142 | 0.230 |
Why?
|
| Crime | 1 | 2005 | 29 | 0.230 |
Why?
|
| Radiography | 5 | 2012 | 71 | 0.230 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2025 | 17 | 0.230 |
Why?
|
| Streptococcal Infections | 1 | 2025 | 37 | 0.230 |
Why?
|
| Creatine Kinase | 4 | 2020 | 22 | 0.230 |
Why?
|
| Fontan Procedure | 3 | 2017 | 11 | 0.230 |
Why?
|
| Poverty Areas | 1 | 2005 | 47 | 0.230 |
Why?
|
| Pre-Eclampsia | 1 | 2026 | 67 | 0.230 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2016 | 45 | 0.230 |
Why?
|
| Glucagonoma | 1 | 2005 | 1 | 0.230 |
Why?
|
| Chemistry, Physical | 4 | 2007 | 50 | 0.230 |
Why?
|
| Linear Models | 4 | 2017 | 317 | 0.230 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2016 | 35 | 0.230 |
Why?
|
| Mutation | 4 | 2014 | 1177 | 0.230 |
Why?
|
| Sex Factors | 5 | 2026 | 1028 | 0.230 |
Why?
|
| Chemical Phenomena | 4 | 2007 | 56 | 0.230 |
Why?
|
| Radionuclide Imaging | 4 | 2010 | 29 | 0.220 |
Why?
|
| Data Mining | 3 | 2020 | 30 | 0.220 |
Why?
|
| Chromatography, Supercritical Fluid | 1 | 2004 | 3 | 0.220 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2025 | 70 | 0.220 |
Why?
|
| Fluoroquinolones | 1 | 2024 | 9 | 0.220 |
Why?
|
| Blood Glucose | 3 | 2015 | 389 | 0.220 |
Why?
|
| Motivation | 1 | 2009 | 513 | 0.220 |
Why?
|
| Phantoms, Imaging | 2 | 2020 | 28 | 0.220 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2004 | 36 | 0.220 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 134 | 0.220 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 107 | 0.220 |
Why?
|
| Rare Diseases | 1 | 2024 | 17 | 0.220 |
Why?
|
| Observer Variation | 4 | 2020 | 59 | 0.220 |
Why?
|
| Trace Elements | 3 | 2010 | 35 | 0.220 |
Why?
|
| Angina Pectoris | 1 | 2004 | 20 | 0.220 |
Why?
|
| Survival Rate | 4 | 2026 | 355 | 0.220 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 93 | 0.220 |
Why?
|
| Mental Disorders | 2 | 2022 | 392 | 0.220 |
Why?
|
| Blood Flow Velocity | 3 | 2018 | 87 | 0.220 |
Why?
|
| Photography, Dental | 3 | 2012 | 3 | 0.220 |
Why?
|
| Iodine | 2 | 2014 | 11 | 0.220 |
Why?
|
| Food Additives | 1 | 2004 | 2 | 0.210 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 15 | 0.210 |
Why?
|
| Cyclodextrins | 1 | 2004 | 11 | 0.210 |
Why?
|
| Prevalence | 9 | 2025 | 1612 | 0.210 |
Why?
|
| Emigration and Immigration | 1 | 2024 | 85 | 0.210 |
Why?
|
| Cross-Over Studies | 5 | 2026 | 115 | 0.210 |
Why?
|
| Uremia | 1 | 2004 | 3 | 0.210 |
Why?
|
| Ritanserin | 1 | 2004 | 3 | 0.210 |
Why?
|
| Endothelin-1 | 1 | 2004 | 57 | 0.210 |
Why?
|
| Ticlopidine | 1 | 2004 | 17 | 0.210 |
Why?
|
| Cell Adhesion | 2 | 2016 | 238 | 0.210 |
Why?
|
| Preoperative Care | 2 | 2021 | 32 | 0.210 |
Why?
|
| Blood Pressure | 5 | 2016 | 666 | 0.210 |
Why?
|
| beta-Cyclodextrins | 1 | 2004 | 35 | 0.210 |
Why?
|
| Arthritis | 2 | 2014 | 18 | 0.210 |
Why?
|
| Artemisinins | 1 | 2024 | 19 | 0.210 |
Why?
|
| Laparoscopy | 2 | 2016 | 59 | 0.210 |
Why?
|
| Mammaplasty | 1 | 2004 | 7 | 0.210 |
Why?
|
| Diabetic Neuropathies | 1 | 2004 | 12 | 0.210 |
Why?
|
| Rheumatology | 2 | 2014 | 19 | 0.210 |
Why?
|
| Vasoconstriction | 1 | 2004 | 42 | 0.210 |
Why?
|
| Coronary Vessels | 4 | 2015 | 92 | 0.210 |
Why?
|
| Phenotype | 5 | 2024 | 780 | 0.210 |
Why?
|
| Tyrosine | 1 | 2004 | 120 | 0.210 |
Why?
|
| Aqueous Humor | 1 | 2003 | 18 | 0.210 |
Why?
|
| Focus Groups | 1 | 2026 | 423 | 0.210 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2003 | 3 | 0.210 |
Why?
|
| Platelet Activation | 1 | 2003 | 6 | 0.210 |
Why?
|
| Hypoglycemic Agents | 3 | 2015 | 184 | 0.200 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 532 | 0.200 |
Why?
|
| Pain | 2 | 2023 | 290 | 0.200 |
Why?
|
| Anorexia Nervosa | 1 | 2023 | 6 | 0.200 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 9 | 0.200 |
Why?
|
| Teaching Rounds | 1 | 2023 | 4 | 0.200 |
Why?
|
| Staphylococcus aureus | 1 | 2024 | 94 | 0.200 |
Why?
|
| Immunity | 1 | 2003 | 61 | 0.200 |
Why?
|
| Length of Stay | 1 | 2005 | 229 | 0.200 |
Why?
|
| Ganciclovir | 1 | 2023 | 4 | 0.200 |
Why?
|
| Antimalarials | 1 | 2024 | 64 | 0.200 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 182 | 0.200 |
Why?
|
| Urinary Tract Infections | 1 | 2023 | 44 | 0.200 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2023 | 14 | 0.190 |
Why?
|
| Prosthesis Failure | 4 | 2011 | 19 | 0.190 |
Why?
|
| Malaria | 1 | 2024 | 90 | 0.190 |
Why?
|
| Heart Rate | 4 | 2021 | 266 | 0.190 |
Why?
|
| Biosensing Techniques | 2 | 2025 | 136 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2017 | 33 | 0.190 |
Why?
|
| Dobutamine | 1 | 2022 | 7 | 0.190 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2017 | 13 | 0.190 |
Why?
|
| Vasodilation | 2 | 2006 | 64 | 0.190 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 1063 | 0.190 |
Why?
|
| Capsule Endoscopy | 1 | 2022 | 2 | 0.190 |
Why?
|
| Aluminum | 1 | 2002 | 39 | 0.190 |
Why?
|
| Occupational Diseases | 2 | 2017 | 53 | 0.190 |
Why?
|
| Organometallic Compounds | 4 | 2016 | 71 | 0.190 |
Why?
|
| Postmenopause | 2 | 2014 | 141 | 0.190 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2023 | 51 | 0.190 |
Why?
|
| Rib Fractures | 1 | 2022 | 3 | 0.190 |
Why?
|
| Disease Models, Animal | 7 | 2018 | 1596 | 0.190 |
Why?
|
| Cold Temperature | 1 | 2022 | 40 | 0.190 |
Why?
|
| Athletes | 3 | 2011 | 62 | 0.190 |
Why?
|
| Paracentesis | 1 | 2022 | 1 | 0.190 |
Why?
|
| Ascites | 1 | 2022 | 6 | 0.190 |
Why?
|
| Monoterpenes | 1 | 2002 | 10 | 0.190 |
Why?
|
| Nose | 1 | 2002 | 11 | 0.180 |
Why?
|
| Epithelial Cells | 2 | 2016 | 434 | 0.180 |
Why?
|
| Vasoplegia | 1 | 2021 | 1 | 0.180 |
Why?
|
| Area Under Curve | 3 | 2017 | 95 | 0.180 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 9 | 0.180 |
Why?
|
| Pancreatic Diseases | 1 | 2002 | 6 | 0.180 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 164 | 0.180 |
Why?
|
| Hypotension | 1 | 2021 | 24 | 0.180 |
Why?
|
| Postoperative Hemorrhage | 1 | 2021 | 15 | 0.180 |
Why?
|
| Quantitative Trait Loci | 1 | 2022 | 88 | 0.180 |
Why?
|
| Tobacco Use Disorder | 1 | 2005 | 250 | 0.180 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 83 | 0.180 |
Why?
|
| Criminals | 1 | 2022 | 18 | 0.180 |
Why?
|
| Climate Change | 1 | 2022 | 53 | 0.180 |
Why?
|
| Depression | 1 | 2009 | 863 | 0.180 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 88 | 0.180 |
Why?
|
| Rupture, Spontaneous | 2 | 2017 | 7 | 0.180 |
Why?
|
| Radiology | 1 | 2021 | 12 | 0.180 |
Why?
|
| Glycine | 2 | 2017 | 47 | 0.180 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2021 | 2 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 147 | 0.170 |
Why?
|
| Health Records, Personal | 1 | 2021 | 6 | 0.170 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 4 | 2006 | 83 | 0.170 |
Why?
|
| Europe | 4 | 2025 | 115 | 0.170 |
Why?
|
| Calcinosis | 1 | 2002 | 62 | 0.170 |
Why?
|
| Models, Animal | 1 | 2002 | 151 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 89 | 0.170 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 830 | 0.170 |
Why?
|
| Tissue Donors | 2 | 2015 | 53 | 0.170 |
Why?
|
| Biliary Tract Diseases | 2 | 2013 | 2 | 0.170 |
Why?
|
| Rehabilitation Centers | 1 | 2021 | 10 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2021 | 6 | 0.170 |
Why?
|
| Fluoroscopy | 3 | 2017 | 10 | 0.170 |
Why?
|
| Ambulatory Care | 1 | 2022 | 81 | 0.170 |
Why?
|
| Social Class | 2 | 2022 | 291 | 0.170 |
Why?
|
| Adenosine | 2 | 2016 | 62 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2023 | 195 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2021 | 38 | 0.170 |
Why?
|
| Thiamine Pyrophosphate | 1 | 2020 | 3 | 0.170 |
Why?
|
| Spacecraft | 1 | 2020 | 3 | 0.170 |
Why?
|
| Aerospace Medicine | 1 | 2020 | 3 | 0.170 |
Why?
|
| Thermodynamics | 4 | 2014 | 229 | 0.170 |
Why?
|
| Diphosphonates | 3 | 2015 | 19 | 0.170 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2020 | 3 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 112 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 28 | 0.160 |
Why?
|
| Queensland | 1 | 2020 | 2 | 0.160 |
Why?
|
| Hemoglobins | 2 | 2015 | 113 | 0.160 |
Why?
|
| Culture Media | 1 | 2020 | 96 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2020 | 12 | 0.160 |
Why?
|
| Antioxidants | 4 | 2010 | 443 | 0.160 |
Why?
|
| Secondary Prevention | 2 | 2020 | 48 | 0.160 |
Why?
|
| Cytokines | 1 | 2004 | 678 | 0.160 |
Why?
|
| Occult Blood | 1 | 2020 | 32 | 0.160 |
Why?
|
| Electrochemical Techniques | 1 | 2020 | 32 | 0.160 |
Why?
|
| Joint Prosthesis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Syndrome | 5 | 2019 | 73 | 0.160 |
Why?
|
| Criminal Law | 1 | 2020 | 28 | 0.160 |
Why?
|
| Swine | 2 | 2019 | 212 | 0.160 |
Why?
|
| Nanoparticles | 2 | 2016 | 460 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2020 | 63 | 0.160 |
Why?
|
| Nitrogen | 1 | 2021 | 84 | 0.160 |
Why?
|
| Limit of Detection | 2 | 2020 | 94 | 0.160 |
Why?
|
| Statistics, Nonparametric | 3 | 2012 | 113 | 0.160 |
Why?
|
| Body Image | 2 | 2012 | 89 | 0.160 |
Why?
|
| Genital Diseases, Male | 1 | 2019 | 2 | 0.160 |
Why?
|
| Prosthesis Implantation | 3 | 2024 | 16 | 0.160 |
Why?
|
| Seminal Vesicles | 1 | 2019 | 9 | 0.160 |
Why?
|
| Environmental Pollutants | 1 | 2002 | 201 | 0.160 |
Why?
|
| Metaplasia | 1 | 2020 | 39 | 0.160 |
Why?
|
| Dyslipidemias | 2 | 2012 | 48 | 0.160 |
Why?
|
| Cysts | 1 | 2019 | 10 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2025 | 502 | 0.160 |
Why?
|
| Cerebral Cortex | 3 | 2011 | 306 | 0.160 |
Why?
|
| Prednisolone | 1 | 2019 | 16 | 0.160 |
Why?
|
| Intestines | 1 | 2020 | 71 | 0.150 |
Why?
|
| Radiation Dosage | 4 | 2020 | 37 | 0.150 |
Why?
|
| Periodicity | 1 | 2019 | 34 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 54 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2019 | 16 | 0.150 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 16 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 78 | 0.150 |
Why?
|
| Atmospheric Pressure | 3 | 2004 | 11 | 0.150 |
Why?
|
| Hospital Mortality | 3 | 2026 | 210 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 74 | 0.150 |
Why?
|
| Blood Proteins | 2 | 2018 | 77 | 0.150 |
Why?
|
| Ostreidae | 1 | 2019 | 1 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 9 | 0.150 |
Why?
|
| Metformin | 3 | 2015 | 75 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2019 | 91 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2020 | 161 | 0.150 |
Why?
|
| Horses | 1 | 2019 | 28 | 0.150 |
Why?
|
| Debridement | 1 | 2018 | 4 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2018 | 7 | 0.150 |
Why?
|
| Intestinal Fistula | 1 | 2018 | 4 | 0.150 |
Why?
|
| Video-Assisted Surgery | 1 | 2018 | 4 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 10 | 0.150 |
Why?
|
| Propensity Score | 1 | 2019 | 59 | 0.150 |
Why?
|
| Escherichia coli | 2 | 2017 | 460 | 0.150 |
Why?
|
| Sheep | 1 | 2019 | 77 | 0.150 |
Why?
|
| Benzaldehydes | 2 | 2011 | 8 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 193 | 0.150 |
Why?
|
| Western Australia | 3 | 2025 | 7 | 0.150 |
Why?
|
| Pregnancy | 7 | 2026 | 1772 | 0.150 |
Why?
|
| Genome, Fungal | 1 | 2018 | 28 | 0.140 |
Why?
|
| Pyrazines | 2 | 2011 | 32 | 0.140 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 10 | 0.140 |
Why?
|
| Heart Function Tests | 3 | 2018 | 12 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 375 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2014 | 9 | 0.140 |
Why?
|
| Brucellosis, Bovine | 1 | 2018 | 2 | 0.140 |
Why?
|
| Inflammation | 5 | 2018 | 758 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2018 | 30 | 0.140 |
Why?
|
| Health Care Costs | 2 | 2023 | 91 | 0.140 |
Why?
|
| Glipizide | 2 | 2015 | 5 | 0.140 |
Why?
|
| Smoking | 1 | 2005 | 1024 | 0.140 |
Why?
|
| Animal Husbandry | 1 | 2018 | 21 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 638 | 0.140 |
Why?
|
| Starch | 2 | 2009 | 12 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 306 | 0.140 |
Why?
|
| Recurrence | 4 | 2023 | 152 | 0.140 |
Why?
|
| Ascomycota | 1 | 2018 | 21 | 0.140 |
Why?
|
| Viscosity | 4 | 2012 | 46 | 0.140 |
Why?
|
| Feces | 2 | 2017 | 132 | 0.140 |
Why?
|
| Abattoirs | 1 | 2017 | 2 | 0.140 |
Why?
|
| Sterilization | 1 | 2017 | 3 | 0.140 |
Why?
|
| Virulence | 1 | 2018 | 246 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2017 | 2 | 0.130 |
Why?
|
| Echoencephalography | 1 | 2017 | 4 | 0.130 |
Why?
|
| Fourier Analysis | 1 | 2017 | 45 | 0.130 |
Why?
|
| Nutritional Requirements | 2 | 2014 | 33 | 0.130 |
Why?
|
| Alligators and Crocodiles | 1 | 2017 | 9 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2017 | 12 | 0.130 |
Why?
|
| Kidney Calculi | 1 | 2017 | 6 | 0.130 |
Why?
|
| Urologic Surgical Procedures | 1 | 2017 | 5 | 0.130 |
Why?
|
| Passeriformes | 1 | 2018 | 41 | 0.130 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 159 | 0.130 |
Why?
|
| Emergency Treatment | 1 | 2017 | 14 | 0.130 |
Why?
|
| Hydrocephalus | 1 | 2017 | 16 | 0.130 |
Why?
|
| Mental Health | 1 | 2022 | 385 | 0.130 |
Why?
|
| Sampling Studies | 2 | 2014 | 64 | 0.130 |
Why?
|
| Lactates | 2 | 2010 | 9 | 0.130 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2017 | 5 | 0.130 |
Why?
|
| Chickens | 1 | 2019 | 161 | 0.130 |
Why?
|
| Optic Nerve | 1 | 2017 | 30 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2022 | 301 | 0.130 |
Why?
|
| Thyroid Gland | 1 | 2017 | 23 | 0.130 |
Why?
|
| Hair | 2 | 2014 | 38 | 0.130 |
Why?
|
| Patient Positioning | 1 | 2017 | 4 | 0.130 |
Why?
|
| Pelvic Pain | 1 | 2017 | 10 | 0.130 |
Why?
|
| Puberty | 1 | 2017 | 31 | 0.130 |
Why?
|
| Oxygen Consumption | 3 | 2012 | 110 | 0.130 |
Why?
|
| Diet | 3 | 2017 | 826 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2017 | 31 | 0.130 |
Why?
|
| Patient Admission | 1 | 2017 | 50 | 0.130 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Atrioventricular Block | 1 | 2016 | 1 | 0.130 |
Why?
|
| APACHE | 1 | 2016 | 6 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2017 | 69 | 0.130 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 2 | 2013 | 9 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 38 | 0.130 |
Why?
|
| England | 3 | 2014 | 11 | 0.130 |
Why?
|
| Suture Techniques | 1 | 2016 | 10 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 518 | 0.130 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 3 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 93 | 0.130 |
Why?
|
| Serum Albumin | 1 | 2017 | 59 | 0.130 |
Why?
|
| Tricuspid Valve | 1 | 2016 | 12 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2016 | 39 | 0.130 |
Why?
|
| Paintings | 1 | 2016 | 1 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 734 | 0.130 |
Why?
|
| Medical Audit | 2 | 2015 | 26 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 2017 | 48 | 0.130 |
Why?
|
| Paint | 1 | 2016 | 5 | 0.130 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cilia | 1 | 2016 | 31 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2016 | 55 | 0.130 |
Why?
|
| Air Pollutants, Occupational | 1 | 2016 | 10 | 0.130 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2016 | 8 | 0.120 |
Why?
|
| Rats | 5 | 2018 | 3735 | 0.120 |
Why?
|
| Emergency Medicine | 1 | 2016 | 33 | 0.120 |
Why?
|
| Reference Standards | 1 | 2016 | 55 | 0.120 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 116 | 0.120 |
Why?
|
| Chromium | 1 | 2016 | 28 | 0.120 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cobalt | 1 | 2016 | 29 | 0.120 |
Why?
|
| Reperfusion Injury | 2 | 2018 | 58 | 0.120 |
Why?
|
| Aortic Aneurysm | 1 | 2016 | 5 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 209 | 0.120 |
Why?
|
| Cadmium | 1 | 2016 | 56 | 0.120 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 13 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 38 | 0.120 |
Why?
|
| Enema | 2 | 2007 | 10 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2013 | 316 | 0.120 |
Why?
|
| Internationality | 1 | 2016 | 37 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2016 | 60 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 59 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 934 | 0.120 |
Why?
|
| Public Health | 1 | 2020 | 424 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2016 | 34 | 0.120 |
Why?
|
| Models, Biological | 3 | 2014 | 712 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 67 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 149 | 0.120 |
Why?
|
| Dog Diseases | 1 | 2016 | 49 | 0.120 |
Why?
|
| Cardiac Output | 2 | 2012 | 24 | 0.120 |
Why?
|
| Education | 1 | 2016 | 60 | 0.120 |
Why?
|
| Spectrum Analysis | 2 | 2013 | 61 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 58 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 148 | 0.110 |
Why?
|
| Cyclohexanes | 1 | 2015 | 30 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 539 | 0.110 |
Why?
|
| Health Resources | 1 | 2015 | 37 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 247 | 0.110 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 30 | 0.110 |
Why?
|
| Educational Measurement | 1 | 2016 | 102 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2007 | 246 | 0.110 |
Why?
|
| Arsenic | 2 | 2014 | 155 | 0.110 |
Why?
|
| Denervation | 1 | 2015 | 27 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2015 | 63 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2017 | 189 | 0.110 |
Why?
|
| Spinal Dysraphism | 1 | 2014 | 6 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2012 | 38 | 0.110 |
Why?
|
| Glucose | 2 | 2024 | 244 | 0.110 |
Why?
|
| Stathmin | 1 | 2014 | 2 | 0.110 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 57 | 0.110 |
Why?
|
| Arsenic Poisoning | 1 | 2014 | 6 | 0.110 |
Why?
|
| False Negative Reactions | 1 | 2014 | 10 | 0.110 |
Why?
|
| Binding Sites | 3 | 2014 | 671 | 0.110 |
Why?
|
| Motorcycles | 1 | 2014 | 9 | 0.110 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 306 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2014 | 42 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 11 | 0.110 |
Why?
|
| Homicide | 1 | 2014 | 17 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 67 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2014 | 38 | 0.110 |
Why?
|
| Calorimetry | 2 | 2011 | 20 | 0.110 |
Why?
|
| Arthralgia | 1 | 2014 | 12 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 102 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 48 | 0.110 |
Why?
|
| Triiodobenzoic Acids | 1 | 2014 | 1 | 0.110 |
Why?
|
| Computational Biology | 1 | 2017 | 327 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2016 | 281 | 0.110 |
Why?
|
| Curcuma | 1 | 2014 | 5 | 0.110 |
Why?
|
| Communication | 1 | 2016 | 210 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1455 | 0.110 |
Why?
|
| Uncertainty | 2 | 2012 | 32 | 0.110 |
Why?
|
| Saliva | 3 | 2006 | 119 | 0.110 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2014 | 26 | 0.100 |
Why?
|
| Polyethylene Glycols | 2 | 2022 | 108 | 0.100 |
Why?
|
| Single-Blind Method | 5 | 2017 | 54 | 0.100 |
Why?
|
| Manometry | 2 | 2019 | 8 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 38 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 28 | 0.100 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2014 | 24 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 35 | 0.100 |
Why?
|
| Analgesics | 1 | 2014 | 55 | 0.100 |
Why?
|
| Dietary Supplements | 2 | 2014 | 213 | 0.100 |
Why?
|
| Myositis | 1 | 2013 | 7 | 0.100 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2013 | 5 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2020 | 661 | 0.100 |
Why?
|
| Amino Acids, Aromatic | 1 | 2013 | 7 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2015 | 129 | 0.100 |
Why?
|
| Hypophosphatemia | 1 | 2013 | 2 | 0.100 |
Why?
|
| Biliary Tract | 1 | 2013 | 3 | 0.100 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2013 | 7 | 0.100 |
Why?
|
| United States | 6 | 2022 | 5205 | 0.100 |
Why?
|
| Deglutition | 2 | 2012 | 39 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 140 | 0.100 |
Why?
|
| Iliac Artery | 2 | 2004 | 8 | 0.100 |
Why?
|
| Carrageenan | 2 | 2003 | 16 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 20 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 61 | 0.100 |
Why?
|
| Nigeria | 3 | 2018 | 92 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 245 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 3 | 2018 | 74 | 0.100 |
Why?
|
| Personality Inventory | 2 | 2012 | 82 | 0.100 |
Why?
|
| Anesthesia, General | 1 | 2012 | 9 | 0.100 |
Why?
|
| Collagen | 1 | 2014 | 181 | 0.100 |
Why?
|
| Nursing Audit | 1 | 2012 | 2 | 0.100 |
Why?
|
| Thrombosis | 2 | 2025 | 81 | 0.100 |
Why?
|
| X-Rays | 1 | 2012 | 19 | 0.100 |
Why?
|
| Food Preservation | 2 | 2002 | 9 | 0.100 |
Why?
|
| Cariostatic Agents | 1 | 2012 | 4 | 0.100 |
Why?
|
| Powders | 2 | 2002 | 20 | 0.100 |
Why?
|
| Diagnosis, Oral | 1 | 2012 | 2 | 0.100 |
Why?
|
| Molar | 1 | 2012 | 5 | 0.090 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 101 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2017 | 388 | 0.090 |
Why?
|
| Fluorides | 1 | 2012 | 19 | 0.090 |
Why?
|
| Chromatography, Gas | 3 | 2007 | 15 | 0.090 |
Why?
|
| Valproic Acid | 1 | 2012 | 21 | 0.090 |
Why?
|
| Rabbits | 2 | 2004 | 278 | 0.090 |
Why?
|
| Computer Graphics | 1 | 2012 | 18 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2012 | 40 | 0.090 |
Why?
|
| Angioplasty | 1 | 2012 | 2 | 0.090 |
Why?
|
| Water Supply | 1 | 2012 | 60 | 0.090 |
Why?
|
| Body Weight | 3 | 2009 | 429 | 0.090 |
Why?
|
| Nanostructures | 1 | 2014 | 161 | 0.090 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2012 | 25 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 22 | 0.090 |
Why?
|
| Dermatitis | 1 | 2012 | 10 | 0.090 |
Why?
|
| Logistic Models | 4 | 2018 | 1009 | 0.090 |
Why?
|
| Lidocaine | 2 | 2023 | 16 | 0.090 |
Why?
|
| Barium Compounds | 1 | 2012 | 2 | 0.090 |
Why?
|
| Cardiotonic Agents | 2 | 2022 | 40 | 0.090 |
Why?
|
| Occupational Therapy | 1 | 2012 | 14 | 0.090 |
Why?
|
| Honey | 1 | 2012 | 15 | 0.090 |
Why?
|
| Chelating Agents | 1 | 2012 | 52 | 0.090 |
Why?
|
| Electronics | 2 | 2022 | 15 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 282 | 0.090 |
Why?
|
| Mining | 1 | 2012 | 19 | 0.090 |
Why?
|
| Hematinics | 1 | 2011 | 9 | 0.090 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 32 | 0.090 |
Why?
|
| Physical Endurance | 1 | 2011 | 20 | 0.090 |
Why?
|
| Adiposity | 2 | 2015 | 157 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 48 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 458 | 0.090 |
Why?
|
| Cost Control | 1 | 2011 | 9 | 0.090 |
Why?
|
| Phosphates | 2 | 2013 | 54 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2024 | 60 | 0.090 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2011 | 11 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 154 | 0.090 |
Why?
|
| Dental Caries | 1 | 2012 | 57 | 0.090 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 78 | 0.090 |
Why?
|
| Hand Strength | 1 | 2012 | 40 | 0.090 |
Why?
|
| Congenital Abnormalities | 1 | 2011 | 21 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 92 | 0.090 |
Why?
|
| Clinical Protocols | 2 | 2011 | 36 | 0.090 |
Why?
|
| Hernia, Hiatal | 1 | 2011 | 7 | 0.090 |
Why?
|
| Emulsifying Agents | 1 | 2011 | 2 | 0.090 |
Why?
|
| Enbucrilate | 1 | 2011 | 1 | 0.090 |
Why?
|
| Portography | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tissue Adhesives | 1 | 2011 | 2 | 0.090 |
Why?
|
| Binding, Competitive | 1 | 2011 | 109 | 0.090 |
Why?
|
| Aorta | 1 | 2012 | 198 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 590 | 0.090 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2011 | 8 | 0.090 |
Why?
|
| Mutagens | 1 | 2012 | 74 | 0.090 |
Why?
|
| Mechanical Phenomena | 1 | 2011 | 9 | 0.080 |
Why?
|
| Metals, Heavy | 1 | 2012 | 71 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2012 | 187 | 0.080 |
Why?
|
| Ligands | 4 | 2017 | 388 | 0.080 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Transposition of Great Vessels | 1 | 2010 | 3 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 75 | 0.080 |
Why?
|
| Gymnastics | 1 | 2010 | 1 | 0.080 |
Why?
|
| Hemodynamics | 3 | 2021 | 100 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 76 | 0.080 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2010 | 20 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 486 | 0.080 |
Why?
|
| Child Development | 2 | 2017 | 99 | 0.080 |
Why?
|
| Hypertension | 2 | 2015 | 835 | 0.080 |
Why?
|
| Obesity | 1 | 2018 | 1151 | 0.080 |
Why?
|
| Equipment Design | 3 | 2018 | 145 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2012 | 233 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 49 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2010 | 7 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 173 | 0.080 |
Why?
|
| Blood Coagulation Disorders | 1 | 2009 | 8 | 0.080 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 35 | 0.080 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 112 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 2 | 2007 | 30 | 0.080 |
Why?
|
| Ascorbic Acid | 2 | 2022 | 74 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2010 | 51 | 0.080 |
Why?
|
| Cardiac Electrophysiology | 2 | 2021 | 3 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 170 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 80 | 0.080 |
Why?
|
| Wrist | 1 | 2009 | 7 | 0.080 |
Why?
|
| Jewelry | 1 | 2009 | 2 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 158 | 0.080 |
Why?
|
| Capillary Permeability | 2 | 2017 | 36 | 0.080 |
Why?
|
| Feline Acquired Immunodeficiency Syndrome | 1 | 2009 | 2 | 0.080 |
Why?
|
| Immunodeficiency Virus, Feline | 1 | 2009 | 2 | 0.080 |
Why?
|
| Neurogenic Inflammation | 1 | 2009 | 2 | 0.080 |
Why?
|
| Parietal Lobe | 1 | 2009 | 10 | 0.080 |
Why?
|
| Acrylates | 1 | 2009 | 8 | 0.080 |
Why?
|
| Rheology | 2 | 2012 | 51 | 0.080 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2010 | 44 | 0.080 |
Why?
|
| Antirheumatic Agents | 2 | 2006 | 37 | 0.080 |
Why?
|
| Environmental Exposure | 1 | 2012 | 256 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 518 | 0.080 |
Why?
|
| Forelimb | 1 | 2009 | 23 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 529 | 0.070 |
Why?
|
| Anthracyclines | 1 | 2009 | 8 | 0.070 |
Why?
|
| Propiophenones | 1 | 2008 | 2 | 0.070 |
Why?
|
| Heart Failure, Diastolic | 1 | 2008 | 1 | 0.070 |
Why?
|
| Mammography | 1 | 2010 | 212 | 0.070 |
Why?
|
| Mice | 6 | 2018 | 6644 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 2008 | 3 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 153 | 0.070 |
Why?
|
| Dystonic Disorders | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cardiomegaly | 1 | 2009 | 44 | 0.070 |
Why?
|
| beta-Alanine | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pyruvaldehyde | 1 | 2008 | 2 | 0.070 |
Why?
|
| Models, Structural | 1 | 2008 | 12 | 0.070 |
Why?
|
| Friction | 1 | 2008 | 6 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 3 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 162 | 0.070 |
Why?
|
| Asparagine | 1 | 2008 | 9 | 0.070 |
Why?
|
| Cats | 3 | 2017 | 82 | 0.070 |
Why?
|
| Walking | 1 | 2009 | 88 | 0.070 |
Why?
|
| Parkinsonian Disorders | 1 | 2008 | 42 | 0.070 |
Why?
|
| Fructose | 1 | 2008 | 24 | 0.070 |
Why?
|
| Signal Detection, Psychological | 1 | 2008 | 2 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 989 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2023 | 195 | 0.070 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2008 | 3 | 0.070 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2008 | 2 | 0.070 |
Why?
|
| Noise | 1 | 2008 | 10 | 0.070 |
Why?
|
| Pericardium | 1 | 2008 | 15 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2008 | 20 | 0.070 |
Why?
|
| Insulin | 3 | 2015 | 258 | 0.070 |
Why?
|
| Mathematics | 1 | 2008 | 57 | 0.070 |
Why?
|
| Memory | 1 | 2009 | 174 | 0.070 |
Why?
|
| Polymers | 1 | 2009 | 155 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 141 | 0.070 |
Why?
|
| Self Concept | 1 | 2009 | 171 | 0.070 |
Why?
|
| Behavior, Animal | 2 | 2009 | 373 | 0.070 |
Why?
|
| Actinidia | 1 | 2007 | 1 | 0.070 |
Why?
|
| Infant Food | 2 | 2004 | 12 | 0.070 |
Why?
|
| Metals | 1 | 2008 | 114 | 0.070 |
Why?
|
| Receptors, Adrenergic | 1 | 2007 | 10 | 0.070 |
Why?
|
| Heart Aneurysm | 1 | 2007 | 2 | 0.070 |
Why?
|
| Zea mays | 1 | 2009 | 76 | 0.070 |
Why?
|
| Aneurysm, False | 1 | 2007 | 4 | 0.070 |
Why?
|
| Anemia, Dyserythropoietic, Congenital | 1 | 2007 | 1 | 0.070 |
Why?
|
| London | 2 | 2021 | 8 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2016 | 1621 | 0.070 |
Why?
|
| Isometric Contraction | 1 | 2007 | 25 | 0.060 |
Why?
|
| Fats | 1 | 2006 | 2 | 0.060 |
Why?
|
| Gastrointestinal Transit | 1 | 2006 | 1 | 0.060 |
Why?
|
| Hindlimb | 2 | 2009 | 32 | 0.060 |
Why?
|
| Competitive Behavior | 1 | 2006 | 15 | 0.060 |
Why?
|
| alpha-Amylases | 1 | 2006 | 7 | 0.060 |
Why?
|
| Birds | 1 | 2008 | 96 | 0.060 |
Why?
|
| Schizophrenia | 3 | 2012 | 93 | 0.060 |
Why?
|
| Sympathetic Nervous System | 1 | 2007 | 57 | 0.060 |
Why?
|
| Chaperonin 10 | 1 | 2006 | 2 | 0.060 |
Why?
|
| Appendicitis | 1 | 2006 | 18 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2008 | 232 | 0.060 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 70 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 26 | 0.060 |
Why?
|
| Thyroxine | 2 | 2017 | 22 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2012 | 490 | 0.060 |
Why?
|
| Insufflation | 1 | 2006 | 1 | 0.060 |
Why?
|
| Wasps | 1 | 2006 | 27 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 2676 | 0.060 |
Why?
|
| Triiodothyronine | 2 | 2017 | 36 | 0.060 |
Why?
|
| Cholangiography | 1 | 2006 | 4 | 0.060 |
Why?
|
| Ankle Brachial Index | 1 | 2026 | 11 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 37 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2016 | 259 | 0.060 |
Why?
|
| Cause of Death | 2 | 2018 | 186 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 21 | 0.060 |
Why?
|
| Appendix | 1 | 2006 | 4 | 0.060 |
Why?
|
| Regional Blood Flow | 2 | 2006 | 53 | 0.060 |
Why?
|
| Posture | 1 | 2006 | 61 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 241 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2006 | 141 | 0.060 |
Why?
|
| Candy | 1 | 2005 | 1 | 0.060 |
Why?
|
| Chewing Gum | 1 | 2005 | 1 | 0.060 |
Why?
|
| Weight Gain | 2 | 2023 | 139 | 0.060 |
Why?
|
| Citric Acid | 1 | 2005 | 15 | 0.060 |
Why?
|
| Alcoholic Beverages | 1 | 2005 | 16 | 0.060 |
Why?
|
| Soybean Proteins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 240 | 0.060 |
Why?
|
| Respiratory Mechanics | 2 | 2004 | 27 | 0.060 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 20 | 0.060 |
Why?
|
| Critical Illness | 1 | 2026 | 47 | 0.060 |
Why?
|
| Saccharin | 1 | 2005 | 9 | 0.060 |
Why?
|
| Anthropology, Cultural | 1 | 2025 | 12 | 0.060 |
Why?
|
| Temporal Arteries | 1 | 2025 | 3 | 0.060 |
Why?
|
| Desiccation | 1 | 2005 | 10 | 0.060 |
Why?
|
| Parents | 1 | 2009 | 370 | 0.060 |
Why?
|
| Radiology Department, Hospital | 1 | 2005 | 1 | 0.060 |
Why?
|
| Beverages | 2 | 2004 | 66 | 0.060 |
Why?
|
| Freeze Drying | 1 | 2005 | 29 | 0.060 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2005 | 1 | 0.060 |
Why?
|
| Microwaves | 1 | 2005 | 29 | 0.060 |
Why?
|
| G-Quadruplexes | 1 | 2025 | 7 | 0.060 |
Why?
|
| Drug Stability | 1 | 2005 | 129 | 0.060 |
Why?
|
| Humidity | 1 | 2005 | 12 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2005 | 23 | 0.060 |
Why?
|
| Heptanoic Acids | 1 | 2005 | 12 | 0.060 |
Why?
|
| Simvastatin | 1 | 2005 | 29 | 0.060 |
Why?
|
| Elbow Joint | 1 | 2004 | 2 | 0.060 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 4 | 0.060 |
Why?
|
| Dietary Proteins | 1 | 2004 | 35 | 0.050 |
Why?
|
| Arthroplasty, Replacement | 1 | 2004 | 7 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 48 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2006 | 230 | 0.050 |
Why?
|
| Pyrroles | 1 | 2005 | 72 | 0.050 |
Why?
|
| Yogurt | 1 | 2004 | 4 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 13 | 0.050 |
Why?
|
| Diuresis | 1 | 2004 | 7 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 263 | 0.050 |
Why?
|
| Rupture | 1 | 2004 | 5 | 0.050 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 2004 | 2 | 0.050 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2004 | 5 | 0.050 |
Why?
|
| Ear | 1 | 2004 | 4 | 0.050 |
Why?
|
| Cheese | 1 | 2004 | 4 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 22 | 0.050 |
Why?
|
| Phylogeny | 2 | 2018 | 769 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 40 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2004 | 7 | 0.050 |
Why?
|
| Indans | 1 | 2004 | 14 | 0.050 |
Why?
|
| Delphi Technique | 2 | 2014 | 34 | 0.050 |
Why?
|
| Aluminum Compounds | 1 | 2004 | 10 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2018 | 430 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2004 | 34 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 384 | 0.050 |
Why?
|
| Prednisone | 2 | 2017 | 31 | 0.050 |
Why?
|
| Immune System | 1 | 2003 | 41 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2024 | 67 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2004 | 78 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 125 | 0.050 |
Why?
|
| Vitamin E | 1 | 2004 | 62 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2024 | 96 | 0.050 |
Why?
|
| Computer Systems | 2 | 2014 | 19 | 0.050 |
Why?
|
| Agaricales | 1 | 2003 | 8 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2023 | 35 | 0.050 |
Why?
|
| Thinness | 1 | 2023 | 32 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2023 | 7 | 0.050 |
Why?
|
| Computer Simulation | 3 | 2013 | 408 | 0.050 |
Why?
|
| Alleles | 2 | 2015 | 352 | 0.050 |
Why?
|
| Garlic | 1 | 2003 | 31 | 0.050 |
Why?
|
| Galactans | 1 | 2003 | 2 | 0.050 |
Why?
|
| Pentanols | 1 | 2003 | 3 | 0.050 |
Why?
|
| Mannans | 1 | 2003 | 5 | 0.050 |
Why?
|
| Plant Gums | 1 | 2003 | 7 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2004 | 122 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2004 | 126 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 1869 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 403 | 0.050 |
Why?
|
| Fentanyl | 1 | 2023 | 16 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2023 | 104 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 61 | 0.050 |
Why?
|
| European Union | 1 | 2002 | 6 | 0.050 |
Why?
|
| Doxycycline | 1 | 2023 | 32 | 0.050 |
Why?
|
| Sweetening Agents | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 118 | 0.050 |
Why?
|
| Milrinone | 1 | 2022 | 5 | 0.050 |
Why?
|
| Lactose | 1 | 2002 | 16 | 0.050 |
Why?
|
| Pyrones | 1 | 2002 | 11 | 0.050 |
Why?
|
| High-Throughput Screening Assays | 1 | 2023 | 74 | 0.050 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2002 | 35 | 0.050 |
Why?
|
| Simethicone | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cathartics | 1 | 2022 | 6 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2014 | 66 | 0.050 |
Why?
|
| Breast | 1 | 2004 | 139 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 22 | 0.050 |
Why?
|
| Wales | 1 | 2022 | 5 | 0.050 |
Why?
|
| Thailand | 2 | 2012 | 51 | 0.050 |
Why?
|
| Plasmodium falciparum | 1 | 2024 | 144 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2022 | 10 | 0.050 |
Why?
|
| State Medicine | 1 | 2022 | 8 | 0.050 |
Why?
|
| Neoplasms | 1 | 2013 | 1377 | 0.050 |
Why?
|
| Caproates | 1 | 2002 | 2 | 0.050 |
Why?
|
| Crystallization | 1 | 2002 | 88 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 234 | 0.050 |
Why?
|
| Octanols | 1 | 2002 | 7 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2022 | 10 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 385 | 0.050 |
Why?
|
| Hydrazones | 1 | 2022 | 11 | 0.050 |
Why?
|
| Acetone | 1 | 2002 | 7 | 0.050 |
Why?
|
| Protozoan Proteins | 1 | 2024 | 191 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2002 | 7 | 0.050 |
Why?
|
| Vibrio | 1 | 2002 | 19 | 0.050 |
Why?
|
| Exercise Tolerance | 2 | 2013 | 22 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2002 | 14 | 0.050 |
Why?
|
| Fluorescence | 2 | 2012 | 118 | 0.050 |
Why?
|
| Genomics | 2 | 2014 | 293 | 0.050 |
Why?
|
| Causality | 1 | 2002 | 45 | 0.050 |
Why?
|
| Terpenes | 1 | 2002 | 30 | 0.050 |
Why?
|
| Neurons | 1 | 2009 | 1263 | 0.040 |
Why?
|
| Pharmacists | 1 | 2022 | 61 | 0.040 |
Why?
|
| Furans | 1 | 2002 | 40 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2023 | 346 | 0.040 |
Why?
|
| Plant Leaves | 1 | 2022 | 136 | 0.040 |
Why?
|
| Porosity | 1 | 2021 | 43 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2002 | 63 | 0.040 |
Why?
|
| Bundle of His | 1 | 2021 | 3 | 0.040 |
Why?
|
| Atrioventricular Node | 1 | 2021 | 3 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2021 | 39 | 0.040 |
Why?
|
| Polyethyleneimine | 1 | 2021 | 10 | 0.040 |
Why?
|
| Holidays | 1 | 2021 | 1 | 0.040 |
Why?
|
| Electrochemistry | 1 | 2021 | 38 | 0.040 |
Why?
|
| Minnesota | 1 | 2021 | 41 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 355 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 1766 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 76 | 0.040 |
Why?
|
| Particle Size | 1 | 2002 | 272 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 7 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 258 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 19 | 0.040 |
Why?
|
| Catheterization | 1 | 2020 | 22 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 61 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2020 | 27 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2011 | 6 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2021 | 45 | 0.040 |
Why?
|
| Random Allocation | 2 | 2015 | 147 | 0.040 |
Why?
|
| Cognition | 1 | 2004 | 473 | 0.040 |
Why?
|
| Biomimetics | 1 | 2020 | 15 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2016 | 2157 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 307 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 26 | 0.040 |
Why?
|
| Diet Records | 2 | 2014 | 58 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 159 | 0.040 |
Why?
|
| Quinolines | 2 | 2014 | 78 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2020 | 37 | 0.040 |
Why?
|
| Brain | 2 | 2008 | 1472 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2018 | 549 | 0.040 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2020 | 95 | 0.040 |
Why?
|
| Gastrointestinal Motility | 1 | 2019 | 20 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2014 | 416 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 423 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2020 | 118 | 0.040 |
Why?
|
| Phlebography | 1 | 2019 | 2 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 423 | 0.040 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 6 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 9 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 321 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 332 | 0.040 |
Why?
|
| Defibrillators | 1 | 2018 | 4 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 11 | 0.040 |
Why?
|
| Adaptation, Physiological | 2 | 2011 | 143 | 0.040 |
Why?
|
| Chromosomes, Fungal | 1 | 2018 | 4 | 0.040 |
Why?
|
| Synteny | 1 | 2018 | 19 | 0.040 |
Why?
|
| Memory Disorders | 2 | 2009 | 77 | 0.040 |
Why?
|
| Peptides | 1 | 2002 | 372 | 0.040 |
Why?
|
| Amines | 1 | 2018 | 41 | 0.040 |
Why?
|
| Rodent Control | 1 | 2018 | 1 | 0.040 |
Why?
|
| Endangered Species | 1 | 2018 | 12 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2018 | 35 | 0.040 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2018 | 69 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 704 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 118 | 0.030 |
Why?
|
| Galectins | 1 | 2018 | 30 | 0.030 |
Why?
|
| Conservation of Natural Resources | 1 | 2018 | 48 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2018 | 142 | 0.030 |
Why?
|
| Protective Clothing | 1 | 2017 | 6 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2017 | 51 | 0.030 |
Why?
|
| Biophysics | 1 | 2017 | 38 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 144 | 0.030 |
Why?
|
| Circular Dichroism | 1 | 2017 | 64 | 0.030 |
Why?
|
| Zoonoses | 1 | 2017 | 21 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2017 | 7 | 0.030 |
Why?
|
| Hydronephrosis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Cyclotrons | 1 | 2017 | 1 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2017 | 24 | 0.030 |
Why?
|
| Dehydroascorbic Acid | 1 | 2017 | 3 | 0.030 |
Why?
|
| Choline Deficiency | 1 | 2017 | 4 | 0.030 |
Why?
|
| Methionine | 1 | 2017 | 27 | 0.030 |
Why?
|
| Women's Health Services | 1 | 2017 | 12 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 595 | 0.030 |
Why?
|
| Michigan | 1 | 2017 | 57 | 0.030 |
Why?
|
| Knowledge Bases | 1 | 2017 | 8 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2016 | 42 | 0.030 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 6 | 0.030 |
Why?
|
| Ecosystem | 1 | 2018 | 175 | 0.030 |
Why?
|
| Respiratory Protective Devices | 1 | 2016 | 2 | 0.030 |
Why?
|
| Forecasting | 1 | 2017 | 136 | 0.030 |
Why?
|
| Motor Activity | 1 | 2019 | 437 | 0.030 |
Why?
|
| Microbubbles | 1 | 2016 | 22 | 0.030 |
Why?
|
| Protein Binding | 2 | 2014 | 1082 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2017 | 74 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 515 | 0.030 |
Why?
|
| Computer-Aided Design | 1 | 2016 | 11 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 15 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aortography | 1 | 2016 | 10 | 0.030 |
Why?
|
| Rose Bengal | 1 | 2016 | 3 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2016 | 4 | 0.030 |
Why?
|
| Ulcer | 1 | 2016 | 6 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2016 | 61 | 0.030 |
Why?
|
| Iopamidol | 1 | 2016 | 1 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 876 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 87 | 0.030 |
Why?
|
| Plant Roots | 1 | 2018 | 180 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 49 | 0.030 |
Why?
|
| Membranes, Artificial | 1 | 2016 | 33 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2016 | 54 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 55 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2007 | 260 | 0.030 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 12 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 256 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 70 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2015 | 5 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 457 | 0.030 |
Why?
|
| Materials Testing | 1 | 2016 | 101 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 21 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 91 | 0.030 |
Why?
|
| Partial Pressure | 1 | 2015 | 9 | 0.030 |
Why?
|
| Surface Properties | 1 | 2016 | 160 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 41 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 12 | 0.030 |
Why?
|
| Macaca | 1 | 2015 | 36 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 497 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2015 | 39 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 117 | 0.030 |
Why?
|
| Emergencies | 1 | 2015 | 32 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 204 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 164 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 75 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2016 | 92 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 246 | 0.030 |
Why?
|
| Deficiency Diseases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Eggs | 1 | 2014 | 14 | 0.030 |
Why?
|
| Urinalysis | 1 | 2014 | 34 | 0.030 |
Why?
|
| Folic Acid | 1 | 2014 | 49 | 0.030 |
Why?
|
| Comprehension | 1 | 2014 | 41 | 0.030 |
Why?
|
| Dairy Products | 1 | 2014 | 34 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 37 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 42 | 0.030 |
Why?
|
| Environment | 1 | 2015 | 149 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 1 | 2014 | 61 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 46 | 0.030 |
Why?
|
| Hospitals, County | 1 | 2014 | 2 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2014 | 70 | 0.030 |
Why?
|
| Seasons | 1 | 2014 | 139 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 2014 | 20 | 0.030 |
Why?
|
| World Health Organization | 1 | 2014 | 36 | 0.030 |
Why?
|
| Static Electricity | 1 | 2014 | 86 | 0.030 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2013 | 2 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 11 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2013 | 19 | 0.030 |
Why?
|
| Energy Intake | 1 | 2014 | 164 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 53 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 142 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2018 | 735 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2020 | 719 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 206 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2014 | 103 | 0.030 |
Why?
|
| RNA | 1 | 2015 | 266 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 185 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 75 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 183 | 0.020 |
Why?
|
| Leukocytes | 1 | 2013 | 80 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2014 | 131 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 2012 | 5 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 518 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 140 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2014 | 93 | 0.020 |
Why?
|
| Incisor | 1 | 2012 | 4 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2013 | 165 | 0.020 |
Why?
|
| Ireland | 1 | 2012 | 3 | 0.020 |
Why?
|
| Finland | 1 | 2012 | 15 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 139 | 0.020 |
Why?
|
| Palliative Care | 1 | 2013 | 61 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2012 | 1 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 33 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2012 | 21 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1234 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 188 | 0.020 |
Why?
|
| Deferoxamine | 1 | 2012 | 17 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 73 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 99 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 152 | 0.020 |
Why?
|
| Respiratory Aspiration | 1 | 2012 | 2 | 0.020 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2012 | 3 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 70 | 0.020 |
Why?
|
| Alendronate | 1 | 2012 | 3 | 0.020 |
Why?
|
| Nails | 1 | 2012 | 5 | 0.020 |
Why?
|
| Portugal | 1 | 2012 | 10 | 0.020 |
Why?
|
| Poisoning | 1 | 2012 | 13 | 0.020 |
Why?
|
| Triglycerides | 1 | 2012 | 147 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 21 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2011 | 14 | 0.020 |
Why?
|
| Troponin T | 1 | 2011 | 10 | 0.020 |
Why?
|
| Hawaii | 1 | 2018 | 2011 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 47 | 0.020 |
Why?
|
| Abortion, Eugenic | 1 | 2011 | 1 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 67 | 0.020 |
Why?
|
| Thiophenes | 1 | 2012 | 32 | 0.020 |
Why?
|
| Rest | 1 | 2011 | 32 | 0.020 |
Why?
|
| Fetal Death | 1 | 2011 | 18 | 0.020 |
Why?
|
| Weight Loss | 1 | 2012 | 137 | 0.020 |
Why?
|
| Video Recording | 1 | 2012 | 41 | 0.020 |
Why?
|
| Osteoarthritis, Hip | 1 | 2011 | 6 | 0.020 |
Why?
|
| Africa | 1 | 2011 | 82 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2011 | 12 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 7 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 986 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2011 | 16 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 98 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 24 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2011 | 27 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2013 | 201 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.020 |
Why?
|
| Patient Preference | 1 | 2012 | 60 | 0.020 |
Why?
|
| Light | 1 | 2012 | 185 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 55 | 0.020 |
Why?
|
| Injections | 1 | 2011 | 42 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 48 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 22 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2011 | 55 | 0.020 |
Why?
|
| Pulmonary Ventilation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 47 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 103 | 0.020 |
Why?
|
| Renal Circulation | 1 | 2010 | 20 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 213 | 0.020 |
Why?
|
| Acetates | 1 | 2010 | 32 | 0.020 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 638 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2010 | 17 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 334 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2010 | 21 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blood Component Transfusion | 1 | 2009 | 4 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 242 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2009 | 29 | 0.020 |
Why?
|
| Fever | 1 | 2010 | 62 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 526 | 0.020 |
Why?
|
| Lameness, Animal | 1 | 2009 | 1 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2009 | 22 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2009 | 33 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2009 | 12 | 0.020 |
Why?
|
| Food Packaging | 1 | 2009 | 6 | 0.020 |
Why?
|
| Propanols | 1 | 2009 | 6 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2009 | 75 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 14 | 0.020 |
Why?
|
| Permeability | 1 | 2009 | 67 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2009 | 141 | 0.020 |
Why?
|
| Maze Learning | 1 | 2009 | 113 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 16 | 0.020 |
Why?
|
| Silicon | 1 | 2009 | 17 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 59 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 28 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2009 | 136 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 97 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 411 | 0.020 |
Why?
|
| Viral Load | 1 | 2009 | 348 | 0.020 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Breath Tests | 1 | 2007 | 24 | 0.020 |
Why?
|
| Manganese | 1 | 2008 | 92 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2007 | 38 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Balloon Occlusion | 1 | 2007 | 3 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2007 | 10 | 0.020 |
Why?
|
| Coenzymes | 1 | 2007 | 13 | 0.020 |
Why?
|
| Iron Chelating Agents | 1 | 2007 | 21 | 0.020 |
Why?
|
| Urodynamics | 1 | 2006 | 5 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2007 | 23 | 0.020 |
Why?
|
| Diatrizoate | 1 | 2006 | 1 | 0.020 |
Why?
|
| Diatrizoate Meglumine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Deuterium | 1 | 2006 | 11 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2006 | 20 | 0.020 |
Why?
|
| Plant Oils | 1 | 2006 | 20 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2006 | 18 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 220 | 0.020 |
Why?
|
| Health Status | 1 | 2010 | 442 | 0.020 |
Why?
|
| Ferritins | 1 | 2007 | 63 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2007 | 140 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2006 | 27 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 54 | 0.020 |
Why?
|
| Appendectomy | 1 | 2006 | 17 | 0.020 |
Why?
|
| Aggression | 1 | 2006 | 102 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2006 | 110 | 0.010 |
Why?
|
| Vinblastine | 1 | 2005 | 9 | 0.010 |
Why?
|
| Baculoviridae | 1 | 2005 | 12 | 0.010 |
Why?
|
| Nicardipine | 1 | 2005 | 8 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2005 | 97 | 0.010 |
Why?
|
| Reimbursement Mechanisms | 1 | 2005 | 11 | 0.010 |
Why?
|
| Sulfhydryl Compounds | 1 | 2005 | 51 | 0.010 |
Why?
|
| Miniaturization | 1 | 2005 | 5 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2005 | 83 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 139 | 0.010 |
Why?
|
| Weaning | 1 | 2004 | 16 | 0.010 |
Why?
|
| Catalysis | 1 | 2005 | 187 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 291 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 64 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 186 | 0.010 |
Why?
|
| Cysteine | 1 | 2005 | 103 | 0.010 |
Why?
|
| Coumarins | 1 | 2005 | 45 | 0.010 |
Why?
|
| Joint Instability | 1 | 2004 | 5 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 206 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 296 | 0.010 |
Why?
|
| Models, Anatomic | 1 | 2004 | 18 | 0.010 |
Why?
|
| Citrates | 1 | 2004 | 18 | 0.010 |
Why?
|
| Nasal Cavity | 1 | 2004 | 10 | 0.010 |
Why?
|
| Pharynx | 1 | 2004 | 16 | 0.010 |
Why?
|
| Mastication | 1 | 2004 | 24 | 0.010 |
Why?
|
| Program Development | 1 | 2005 | 240 | 0.010 |
Why?
|
| Chlorides | 1 | 2004 | 59 | 0.010 |
Why?
|
| Electromyography | 1 | 2004 | 69 | 0.010 |
Why?
|
| Minerals | 1 | 2004 | 53 | 0.010 |
Why?
|
| Individuality | 1 | 2004 | 54 | 0.010 |
Why?
|
| Catalase | 1 | 2004 | 110 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2005 | 359 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2004 | 112 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 283 | 0.010 |
Why?
|
| Sulfur Compounds | 1 | 2002 | 7 | 0.010 |
Why?
|
| Nitrogen Compounds | 1 | 2002 | 5 | 0.010 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Rhenium | 1 | 2002 | 12 | 0.010 |
Why?
|
| S-Adenosylmethionine | 1 | 2002 | 41 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2002 | 155 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 280 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 294 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 1410 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 286 | 0.010 |
Why?
|
| Plasmids | 1 | 2002 | 244 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 983 | 0.010 |
Why?
|